{"nctId":"NCT02924064","briefTitle":"Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2016-09"},"conditions":["Type 2 Diabetes Mellitus"],"count":247,"armGroups":[{"label":"Teneligliptin 20mg","type":"EXPERIMENTAL","interventionNames":["Drug: Teneligliptin 20mg","Drug: Metformin ≥ 1000 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Metformin ≥ 1000 mg"]}],"interventions":[{"name":"Teneligliptin 20mg","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Metformin ≥ 1000 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A signed and dated informed consent form obtained from the subject, in accordance.\n* The subject is aged ≥18 years at signature of the informed consent form.\n* Hospitalization status: outpatient.\n* The subject has a documented diagnosis of type 2 diabetes mellitus for at least 3 months at the screening visit (Day -28).\n* The subject's type 2 diabetes mellitus is managed by metformin monotherapy ≥1000 mg/day plus diet and exercise therapy, and the dosage or dose regimen of metformin and diet and exercise regimen has not been changed for at least 8 consecutive weeks at the screening visit (Day -28). Subjects who cannot do exercise due to complication are not limited to this criteria.\n* The subject's HbA1c is ≥ 7.0% and \\< 10.0% at the screening visit (Day -28) and on Day -14.\n\nExclusion Criteria:\n\n* The subject has a history of type 1 diabetes mellitus or a secondary form of diabetes.\n* The subject has received insulin within 1 year prior to the screening visit (Day -28), with the exception of insulin therapy during hospitalization or insulin therapy for medical conditions not requiring hospitalization (\\< 2 weeks' duration).\n* The subject has received an anti-diabetic drug within 8 weeks prior to the screening visit (Day -28).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Changes in HbA1c at Week 24","description":"The change in HbA1c from baseline to Week 24 in Teneligliptin compared to Placebo was performed on FAS.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"0.07"},{"groupId":"OG001","value":"-0.01","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"The Changes in Fasting Plasma Glucose (FPG) at Week 24","description":"The change in FPG from baseline to Week 24 in Teneligliptin compared to Placebo was performed on FAS.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.5","spread":"3.3"},{"groupId":"OG001","value":"3.0","spread":"3.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":124},"commonTop":["Upper respiratory tract infection","Hyperuricaemia","Hyperlipidaemia","Proteinuria","Hypertension"]}}}